Yvonne Schrage, MD, PhD

Surgical Oncologist
Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands, Netherlands

Presentation(s):

• 61: Surgical considerations for tumor-infiltrating lymphocyte (TIL) therapy in melanoma: results from a randomized phase 3 trial.

  Thursday, March 21, 2024
  2:07pm – 2:17pm ET

• 59: Surgical considerations for resecting the index lymph node after neo-adjuvant checkpoint inhibitors: lessons learned from the PRADO trial

  Friday, March 22, 2024
  2:02pm – 2:14pm ET